Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Obinutuzumab (Gazyva)

decorative image of the issue cover

Published July 3, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses obinutuzumab (Gazyva), 25 mg/mL, concentrate for solution for intravenous infusion.
  • Indication: For the treatment of adult patients with active lupus nephritis who are receiving standard therapy.